accuracy of 99mtc (v)-dimercaptosuccinic acid scintigraphy and fecal calprotectin compared with colonoscopy in localizing active lesions in inflammatory bowel disease

introduction due to limitation of colonoscopy in assessing the entire bowel and patients’ intolerance in inflammatory bowel disease (ibd), in the current study, we aimed to prospectively compare the accuracy of 99m tc(v)-dimercaptosuccinic acid (dmsa) and fecal calprotectin with ileocolonoscopy as new methods for localizing inflammations. methods current prospective study conducted between 2012 and 2014 on 30 patients with ibd attending gastroenterology clinic of tehran university of medical sciences. fecal calprotectin and disease activity were measured for all participants and all of them underwent 99m tc (v)-dmsa scintigraphy and colonoscopy. the accuracy of 99m tc (v)-dmsa scintigraphy and calprotectin in localizing bowel lesions were calculated. results a total of 22 patients with ulcerative colitis (uc) and 8 patients with crohn’s disease (cd) were evaluated in our study. sensitivity, positive likelihood ratio (plr), and positive predictive value (ppv) of scintigraphy and calprotectin over colonoscopy in localization of uc lesions were 86.36%, 0.86%, 100.00% and 90.91%, 0.91, and 100.00%, respectively. meanwhile, it showed 66.67% sensitivity and 81.25% specificity with plr=3.56, negative likelihood ratio (nlr)=0.41, ppv=84.21%, and negative predictive value (npv)= 61.90% in localizing lesions in patients with cd. the calprotectin level had sensitivity, plr, and ppv of 90.00%, 0.90, and 100.00% in detecting active disease over colonoscopy, respectively. conclusion: the 99m tc (v)-dmsa scintigraphy would be an accurate method for detecting active inflammation in follow-up of patients with ibd and  assessing response to treatment as a non-invasive and complementary method beside colonoscopy for more accurate diagnosis of cd or uc.